JIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA

Stock News

Mar 17

JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's National Medical Products Administration (NMPA). The therapeutic indication is metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis. This product is a monoclonal antibody injection targeting SIRPα developed by the group. SIRPα is a classic inhibitory receptor that binds with high affinity to its ligand, CD47. Research indicates that the CD47-SIRPα signaling pathway plays a significant role in immune regulation related to metabolic diseases. SIRPα antagonists can positively influence the progression of metabolic diseases by modulating immune cell function and improving tissue microenvironment and metabolic homeostasis. The injection has demonstrated promising therapeutic potential in both in vitro organoid models and in vivo disease models of MASH.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1128209026"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128209026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128209026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128209026","market":"sg","top_or_hot":-1,"title":"JIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA","media":"Stock News","content":"<p>JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's National Medical Products Administration (NMPA). The therapeutic indication is metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis. This product is a monoclonal antibody injection targeting SIRPα developed by the group. SIRPα is a classic inhibitory receptor that binds with high affinity to its ligand, CD47. Research indicates that the CD47-SIRPα signaling pathway plays a significant role in immune regulation related to metabolic diseases. SIRPα antagonists can positively influence the progression of metabolic diseases by modulating immune cell function and improving tissue microenvironment and metabolic homeostasis. The injection has demonstrated promising therapeutic potential in both in vitro organoid models and in vivo disease models of MASH.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIUYUAN GENE's JY47 Injection Receives Implied Clinical Trial Approval from NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-17 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's National Medical Products Administration (NMPA). The therapeutic indication is metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis. This product is a monoclonal antibody injection targeting SIRPα developed by the group. SIRPα is a classic inhibitory receptor that binds with high affinity to its ligand, CD47. Research indicates that the CD47-SIRPα signaling pathway plays a significant role in immune regulation related to metabolic diseases. SIRPα antagonists can positively influence the progression of metabolic diseases by modulating immune cell function and improving tissue microenvironment and metabolic homeostasis. The injection has demonstrated promising therapeutic potential in both in vitro organoid models and in vivo disease models of MASH.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1128209026","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128209026","pubTimestamp":1773739577,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因","BK1161":"生物科技"},"translate_title":"玖源基因JY47注射液获NMPA默示临床试验批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"JIUYUAN GENE (02566) has announced that the Investigational New Drug (IND) application for its independently developed JY47 injection has received implied approval for clinical trials from China's National Medical Products Administration (NMPA). The therapeutic indication is metabolic dysfunction-associated steatohepatitis (MASH) accompanied by liver fibrosis. This product is a monoclonal antibody injection targeting SIRPα developed by the group. SIRPα is a classic inhibitory receptor that binds with high affinity to its ligand, CD47. Research indicates that the CD47-SIRPα signaling pathway plays a significant role in immune regulation related to metabolic diseases. SIRPα antagonists can positively influence the progression of metabolic diseases by modulating immune cell function and improving tissue microenvironment and metabolic homeostasis. The injection has demonstrated promising therapeutic potential in both in vitro organoid models and in vivo disease models of MASH.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}